“The Biggest Bubble of All Time” – Here’s What to Do.

Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.

Kenneth Krogulski net worth and biography

Kenneth Krogulski Biography and Net Worth

Director of Cumberland Pharmaceuticals

Mr. Krogulski joined Cumberland’s Board of Directors in 2017. He has over 40 years of experience in security analysis and portfolio management and is currently the President and Chief Executive Officer of Berkshire Asset Management, LLC, as well as the company’s Chief Investment Officer. Berkshire is a 33-year-old independent SEC registered Pennsylvania based investment advisory firm with over $2.2 billion in assets under supervision. Prior to Berkshire, Mr. Krogulski began his career in financial services in 1979 at First Eastern Bank, N.A., now PNC Financial, as an investment analyst and portfolio manager, where he advanced to Chief Investment Officer of the Trust Department. He then joined Berkshire in 1990 and later led a management buy-out acquiring the company from Legg Mason. Under his leadership Berkshire’s assets under supervision have grown from $600 million in 2006 and are now over $2.2 billion. Currently Mr. Krogulski serves on the board of Allied Services Rehabilitation Hospital and is a Director of Landmark Community Bank (LDKB: NASDAQ). Previously he served as the Director of the Wyoming Valley Health Care System, on the board of the F.M. Kirby Center for the Performing Arts, the Luzerne Foundation and on various other community boards. Mr. Krogulski holds a B.S. in finance from Indiana University of Pennsylvania and earned his M.B.A. from Wilkes University. In addition, he holds the Chartered Financial Analyst designation.

What is Kenneth Krogulski's net worth?: The estimated net worth of Kenneth Krogulski is at least $312,533.20 as of August 17th, 2022. Mr. Krogulski owns 194,120 shares of Cumberland Pharmaceuticals stock worth more than $312,533 as of April 25th. This net worth evaluation does not reflect any other assets that Mr. Krogulski may own. Learn More about Kenneth Krogulski's net worth.
How do I contact Kenneth Krogulski?: The corporate mailing address for Mr. Krogulski and other Cumberland Pharmaceuticals executives is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. Cumberland Pharmaceuticals can also be reached via phone at (615) 255-0068 and via email at [email protected]. Learn More on Kenneth Krogulski's contact information.
Has Kenneth Krogulski been buying or selling shares of Cumberland Pharmaceuticals?: Kenneth Krogulski has not been actively trading shares of Cumberland Pharmaceuticals during the last quarter. Most recently, on Monday, September 26th, Kenneth Krogulski bought 105 shares of Cumberland Pharmaceuticals stock. The stock was acquired at an average cost of $2.49 per share, with a total value of $261.45. Following the completion of the transaction, the director now directly owns 197,075 shares of the company's stock, valued at $490,716.75. Learn More on Kenneth Krogulski's trading history.
Who are Cumberland Pharmaceuticals' active insiders?: Cumberland Pharmaceuticals' insider roster includes Martin Cearnal (SVP), Joseph Galante (Director), A. J. Kazimi (CEO), A.J. Kazimi (CEO), Kenneth Krogulski (Director), and William Sumas (EVP). Learn More on Cumberland Pharmaceuticals' active insiders.

Kenneth Krogulski Insider Trading History at Cumberland Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/26/2022	Buy	105	$2.49	$261.45	197,075
9/23/2022	Buy	105	$2.55	$267.75	196,970
9/21/2022	Buy	105	$2.59	$271.95	196,760
9/19/2022	Buy	105	$2.56	$268.80	196,550
9/16/2022	Buy	115	$2.49	$286.35	196,445
9/14/2022	Buy	115	$2.51	$288.65	196,215
9/12/2022	Buy	115	$2.46	$282.90	195,985
9/8/2022	Buy	115	$2.22	$255.30	195,810
9/6/2022	Buy	115	$2.15	$247.25	195,580
9/2/2022	Buy	115	$2.42	$278.30	195,465
8/31/2022	Buy	115	$2.36	$271.40	195,235
8/29/2022	Buy	115	$2.44	$280.60	195,005
8/26/2022	Buy	110	$2.55	$280.50	194,890
8/24/2022	Buy	110	$2.59	$284.90	194,670
8/22/2022	Buy	110	$2.51	$276.10	194,450
8/19/2022	Buy	110	$2.35	$258.50	194,340
8/17/2022	Buy	110	$2.31	$254.10	194,120
5/29/2022	Buy	127	$2.13	$270.51	187,617
4/16/2022	Buy	94	$2.71	$254.74	184,235
7/30/2021	Buy	85	$3.31	$281.35	14,742
7/28/2021	Buy	85	$3.42	$290.70
7/26/2021	Buy	85	$3.39	$288.15	14,742
7/23/2021	Buy	85	$3.35	$284.75	32,559
7/21/2021	Buy	85	$3.26	$277.10	32,559
7/19/2021	Buy	85	$3.23	$274.55	14,742
7/16/2021	Buy	85	$3.28	$278.80	32,559
7/14/2021	Buy	85	$3.33	$283.05
7/12/2021	Buy	85	$3.33	$283.05	32,559
7/8/2021	Buy	85	$3.18	$270.30
7/6/2021	Buy	85	$3.14	$266.90	172,085
7/1/2021	Buy	85	$2.91	$247.35	172,085
9/27/2019	Buy	65	$5.76	$374.40	161,422
9/18/2019	Buy	130	$4.93	$640.90	161,752
9/16/2019	Buy	65	$4.97	$323.05	161,752
9/13/2019	Buy	130	$5.18	$673.40	161,752
9/4/2019	Buy	65	$4.79	$311.35	161,752
8/27/2019	Buy	130	$5.19	$674.70	161,752
8/23/2019	Buy	65	$5.38	$349.70	161,752
7/22/2019	Buy	65	$5.75	$373.75	158,012
7/19/2019	Buy	65	$5.69	$369.85	158,012
6/10/2019	Buy	65	$6.08	$395.20	158,012
6/7/2019	Buy	65	$6.06	$393.90	158,012
6/5/2019	Buy	55	$6.66	$366.30	158,012
6/3/2019	Buy	65	$6.49	$421.85	158,012
5/30/2019	Buy	65	$6.58	$427.70	158,012
5/28/2019	Buy	65	$6.64	$431.60	158,012
5/24/2019	Buy	65	$6.66	$432.90	158,012
4/9/2019	Buy	1,596	$6.12	$9,767.52	156,682
11/20/2017	Buy	3,300	$7.55	$24,915.00	154,300

Kenneth Krogulski Buying and Selling Activity at Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Company Overview

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $1.61

$1.61

50 Day Range

MA: $1.85

$1.55

$2.21

2 Week Range

Now: $1.61

$1.43

$2.36

Volume

199 shs

Average Volume

11,036 shs

Market Capitalization

$22.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16